Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
IPO Year: 2020
Exchange: NASDAQ
Website: tarsusrx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $75.00 | Outperform | Oppenheimer |
| 5/27/2025 | $72.00 | Buy | H.C. Wainwright |
| 11/20/2023 | $19.00 | Neutral | Goldman |
| 7/18/2023 | $44.00 | Outperform | William Blair |
| 5/18/2023 | Buy | Guggenheim | |
| 8/1/2022 | $40.00 | Overweight | Barclays |
| 12/21/2021 | $40.00 | Buy | HC Wainwright & Co. |
| 11/23/2021 | $55.00 | Outperform | Oppenheimer |
| 10/8/2021 | $50.00 → $65.00 | Strong Buy | Raymond James |
| 6/29/2021 | $39.00 → $50.00 | Strong Buy | Raymond James |